Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma

摘要

Background: Spirometric lung age expresses lung function relative to chronological age. It has been effective in encouraging smoking cessation and has been used in the assessment of asthma. Reslizumab, a humanized anti-interleukin-5 monoclonal antibody, is approved as add-on therapy for adults with severe asthma and elevated blood eosinophils.